Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 5/20 | 0.50 |
| ▸ | JAK1 | P23458 | 2/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | JAK3 | P52333 | 3/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19512840 | 0.87 | ESR2 (0.50) | ESR2NR1H2JAK2JAK1KCNJ1 | |
| SCHEMBL20945423 | 0.84 | KCNJ1 (0.53) | ESR2JAK2KCNJ1NPC1RAB9A | |
| SCHEMBL30474184 | 0.84 | ESR2 (0.56) | ESR2NR1H2JAK2JAK1GPR119 | |
| SCHEMBL31413054 | 0.84 | ESR2 (0.56) | ESR2NR1H2JAK2JAK1GPR119 | |
| SCHEMBL19475593 | 0.82 | MAPT (0.67) | JAK2JAK1GPR119MAPT | |
| SCHEMBL5599594 | 0.81 | ESR2 (0.62) | ESR2NR1H2GPR119RAB9AMAPT | |
| SCHEMBL1187142 | 0.80 | ESR2 (0.60) | ESR2NR1H2JAK2JAK3PTK2 | |
| SCHEMBL1187942 | 0.79 | ESR2 (0.58) | ESR2NR1H2JAK2JAK3PTK2 | |
| SCHEMBL30548176 | 0.78 | ESR2 (0.69) | ESR2NR1H2GPR119MAPTNAMPT | |
| SCHEMBL451998 | 0.78 | ESR2 (0.69) | ESR2NR1H2GPR119MAPTNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | disclosed |
| US-10851108-B2 | Substituted bicyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190127380-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-02 | — | — | US | disclosed |
| WO-2017184662-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127380-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | NR0B1, GRK4, CRKL | ESR2 808/4885NR1H2 32/4885JAK2 1467/4885 |
| US-10851108-B2 | Substituted bicyclic heterocyclic compounds | NR0B1, GRK4, CRKL | ESR2 808/4885NR1H2 32/4885JAK2 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.